Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SF3B3 | Q15393 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267752 | 0.90 | SF3B3 (0.33) | SF3B3 | |
| SCHEMBL1267779 | 0.80 | SF3B3 (0.32) | SF3B3 | |
| SCHEMBL5271410 | 0.79 | SF3B3 (0.35) | SF3B3 | |
| SCHEMBL905723 | 0.78 | SF3B3 (0.49) | SF3B3 | |
| SCHEMBL1504885 | 0.77 | SF3B3 (0.57) | SF3B3 | |
| SCHEMBL1504944 | 0.77 | SF3B3 (0.46) | SF3B3 | |
| SCHEMBL1504930 | 0.77 | SF3B3 (0.44) | SF3B3 | |
| SCHEMBL905710 | 0.77 | SF3B3 (0.43) | SF3B3 | |
| SCHEMBL905687 | 0.76 | SF3B3 (0.45) | SF3B3 | |
| SCHEMBL1505072 | 0.76 | SF3B3 (0.51) | SF3B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292610-A1 | Macrolides with VEGF transcription suppression activity | MERCIAN CORPORATION (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2053393-A1 | PLADIENOLIDE TARGET MOLECULE, COMPOUND CAPABLE OF BINDING TO THE TARGET MOLECULE, AND SCREENING METHOD FOR THE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20060079572-A1 | Novel bioactive substance | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | disclosed |
| EP-1380579-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079572-A1 | Novel bioactive substance | CASP7, MMP7, BMP4 | SF3B3 2363/4885 |
| US-20090227795-A1 | TARGET MOLECULES OF PLADIENOLIDES, COMPOUNDS BINDING TO SUCH TARGET MOLECULES, AND SCREENING METHOD THEREOF | SF3B3, SF3B2, SF3B1 | SF3B3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.